Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins

Circulating non-coding RNAs in recurrent and metastatic ovarian cancer

Computational analyses for cancer biology based on exhaustive experimental backgrounds

Dodging the bullet: therapeutic resistance mechanisms in pediatric cancers

Drug-adapted cancer cell lines as preclinical models of acquired resistance

Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets

Emerging consensus on the mechanism of polyspecific substrate recognition by the multidrug transporter P-glycoprotein

Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies

Innate and adaptive resistance mechanisms to arginine deprivation therapies in sarcoma and other cancers

Insights into breast cancer phenotying through molecular omics approaches and therapy response

Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines

Long non-coding RNAs regulation of therapeutic resistance

Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy

Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors

Mechanisms of resistance to anti-angiogenic treatments

Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology

MicroRNAs and cancer drug resistance: over two thousand characters in search of a role

Mitochondrial determinants of chemoresistance

Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies

PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues

Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma

Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators

Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors

Role of circulating tumor cell spheroids in drug resistance

Stress and drug resistance in cancer

Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase

Targeting MYCN and ALK in resistant and relapsing neuroblastoma

Targeting the “undruggable” RAS - new strategies - new hope?

The effects of growth hormone on therapy resistance in cancer

The role of exosomal microRNAs; focus on clinical applications in breast cancer

Use of MRI, metabolomic, and genomic biomarkers to identify mechanisms of chemoresistance in glioma

Genetic variations in triple-negative breast cancers undergoing neo-adjuvant chemotherapy

MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy

Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells: the quest for microRNAs’ involvement in cancer drug resistance

Longitudinal monitoring for the emergence of epidermal growth factor C797S resistance mutations in non-small cell lung cancer using blood-based droplet digital PCR

Enhanced Kat3A/Catenin transcription: a common mechanism of therapeutic resistance

Actions for 0 selected articles

Cancer Drug Resistance
ISSN 2578-532X (Online)


All published articles will preserved here permanently:



All published articles will preserved here permanently: